Novel glucagon-like peptide-1 analogue exhibits potency-driven G-protein biased agonism with promising effects on diabetes and diabetic dry eye syndrome

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are considered as effective treatments for type 2 diabetes. Here, we describe the in vitro characteristics and in vivo anti-diabetic efficacies of a novel GLP-1RA, termed SM102. The in vitro functions of SM102, including GLP-1R kinetic binding par...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Yongna, Wei, Min, Zhang, Ning, Zhang, Xinying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975272/
https://www.ncbi.nlm.nih.gov/pubmed/35184645
http://dx.doi.org/10.1080/21655979.2022.2031418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975272/
https://www.ncbi.nlm.nih.gov/pubmed/35184645
http://dx.doi.org/10.1080/21655979.2022.2031418

Ejemplares similares